{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"36.5"},{"groupId":"OG001","value":"36.7"}]}],"title":"Month 3"},{"categories":[{"measurements":[{"groupId":"OG000","value":"44.8"},{"groupId":"OG001","value":"44.9"}]}],"title":"Month 6"},{"categories":[{"measurements":[{"groupId":"OG000","value":"49.0"},{"groupId":"OG001","value":"52.0"}]}],"title":"Month 9"},{"categories":[{"measurements":[{"groupId":"OG000","value":"51.0"},{"groupId":"OG001","value":"53.1"}]}],"title":"Month 12"}],"denoms":[{"counts":[{"groupId":"OG000","value":"96"},{"groupId":"OG001","value":"98"}],"units":"Participants"}],"description":"CR as per IMWG criteria is negative immunofixation on serum and urine and disappearance of soft tissue plasmacytomas and \\<5 percent plasma cells in bone marrow.","groups":[{"description":"Participants who completed induction phase entered in the consolidated treatment phase and received thalidomide 100 mg orally, once daily until disease progression (up to maximum of 12 months) and prednisolone 50 mg orally, on every alternate day until disease progression.","id":"OG000","title":"Thalidomide + Prednisolone [TP Consolidation]"},{"description":"Participants who completed induction phase entered in the consolidated treatment phase and received bortezomib 1.3 mg/m\\^2 SC every 2 weeks for 32 weeks in addition to thalidomide 100 mg orally, once daily for a maximum of 12 months or until disease progression and prednisolone 50 mg orally, on every alternate day until disease progression.","id":"OG001","title":"Bortezomib + Thalidomide + Prednisolone [VTP Consolidation]"}],"paramType":"NUMBER","populationDescription":"All response-evaluable-randomized analysis set was defined as all participants in the response-evaluable-induction set (all participants who received at least 1 dose of study medication in the induction phase and had measurable disease at baseline) who were randomized to receive consolidation treatment.","reportingStatus":"POSTED","timeFrame":"Months 3, 6, 9 and 12","title":"Consolidation Phase: Percentage of Participants With Complete Response (CR) at Months 3, 6, 9 and 12","type":"SECONDARY","unitOfMeasure":"percentage of participants"}